Who has invested in HepaRegeniX?

Vesalius Biocapital IV are named among the investors backing HepaRegeniX.

HepaRegeniX Funding: $39M Raised, Series C (2024)

HepaRegeniX funding overview

HepaRegeniX is based in Tübingen, Germany. HepaRegeniX has raised $39M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series C announced in July 2024. The round record for HepaRegeniX runs through 2024; nothing later has been disclosed. Investors on record include Vesalius Biocapital IV.

HepaRegeniX at a glance

Total raised: $39M
Latest round: Series C
Latest round date: July 2024
Headquarters: Tübingen, Germany
Notable investors: Vesalius Biocapital IV

Frequently asked about HepaRegeniX funding

How much has HepaRegeniX raised?: HepaRegeniX has raised $39M in total disclosed funding across the rounds on record.
Who has invested in HepaRegeniX?: Vesalius Biocapital IV are named among the investors backing HepaRegeniX.
What was the latest HepaRegeniX funding round?: The most recent disclosed round is a Series C, announced in July 2024.
Where is HepaRegeniX based?: HepaRegeniX is based in Tübingen, Germany.
When did HepaRegeniX last raise?: The last disclosed HepaRegeniX round closed in July 2024 at Series C.

Every HepaRegeniX figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies in Tübingen at a similar stage.

HepaRegeniX Funding: $39M Raised, Series C (2024)

HepaRegeniX funding overview

HepaRegeniX at a glance

Frequently asked about HepaRegeniX funding

Companies related to HepaRegeniX (33)

Browse related funding lists (3)